The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010Macrophage Precursors as Biomarker for LRRK2-associated Parkinson disease
Objective/Rationale:
LRRK2 mutations significantly contribute to the development of Parkinson Disease, a multisystem disorder. Neuronal loss is a prerequisite to develop the disease and a crosstalk... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010Increased Dopamine Turnover as a Manifestation of LRRK2 Mutation
Objective/Rationale:
Mutations in LRRK2 represent the single most important cause of dominantly inherited Parkinson’s. We have previously shown that people with LRRK2 mutations have abnormal dopamine... -
Novel Hypotheses in Parkinson's Disease, 2010Characterization of PP2A as a Novel Therapeutic Target and a Biomarker of PD
Objective/Rationale:
Protein phosphatase 2A (PP2A) is a key enzyme that dephosphorylates proteins. PP2A deficits may be critical causes of Parkinson’s disease (PD) - abnormalities in PP2A levels and... -
Understanding LRRK2 Biology, 2010Characterization of LRRK2 Cellular and Signaling Pathways
Promising Outcomes of Original Grant:
In the original funded grant, we propose to identify LRRK2 substrates using a chemical genetics approach. We have developed suitable methods and key reagents that... -
Alpha-Synuclein Therapeutics, 2010Neuroprotective efficacy of RAB3B in pre-clinical models of alpha-synucleinopathy
Objective/Rationale:
In Parkinson’s disease, the major motor symptoms are caused by the degeneration of dopamine producing neurons in the substantia nigra pars compacta. We have identified a... -
Alpha-Synuclein Therapeutics, 2010Testing of Davunetide for Intranasal Administration in Pre-clinical Models Over Expressing Alpha-synuclein
Objective/Rationale:
Davunetide is an investigational drug with the potential to treat Parkinson disease and is currently in a clinical trial for progressive supranuclear palsy, a rare progressive...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.